Printer Friendly

Adenosine Therapeutics Awarded Two Patents for the Treatment Of Inflammatory Diseases With Adenosine A2A Agonists.

CHARLOTTESVILLE, Va., Nov. 6 /PRNewswire/ -- Adenosine Therapeutics, LLC announced today the issue of two United States patents for the treatment of a wide-ranging group of inflammatory diseases with adenosine A2A agonists. The patents are 6,531,457 and 6,514,949, Methods and Compositions for Treating the Inflammatory Response.

"The issuance of these two patents strengthens further the company's strong intellectual property and competitive positions," said Robert S. Capon, CEO and co-founder of Adenosine Therapeutics, LLC. "The patents are also representative of Adenosine Therapeutics' strong position as a leading player in adenosine drug discovery and development."

The inflammatory response normally serves a useful purpose by eliminating harmful pathogens, e.g. bacteria, allergens and toxins, from the body. However, in the process of responding to infection, ischemia or trauma, the immune system often "over-responds" and damages healthy tissues. This new class of potent and selective adenosine A2A agonists has been shown, both in vitro and in vivo, to suppress the over-response by decreasing cytokine production and white blood cell activation.

These inventions provide a novel and improved method for treating the inflammatory response in order to improve patient outcomes. "Adenosine Therapeutics hopes to commence phase II clinical trials in 2004 to treat acute inflammation with its most advanced compound, ATL-146e," said Capon.

Adenosine Therapeutics focuses on the discovery and development of novel pharmaceutical products that target adenosine receptor subtypes. Candidates for drug development are identified and screened using the company's state-of- the-art platform technology. The company was founded with the goal of bringing new adenosine-receptor selective drugs into clinical trials for a broad range of potential indications. These drug indications include inflammatory indications, sepsis, heart attack, ischemia-reperfusion injury, vascular injury, spinal cord injury, organ transplantation, COPD, asthma, diabetes, inflammatory bowel disease, retinopathy, epilepsy, Parkinson's disease, and site-specific angiogenesis. The company's most advanced drug development program is in Phase II clinical development.

CONTACT: Robert Capon of Adenosine Therapeutics, LLC, +1-434-971-6800, ext. 201

Web site: http://www.adenrx.com/
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Nov 6, 2003
Words:326
Previous Article:TI Launches High-Performance Analog Third Party Developer Network And Demonstration Platform Tools.
Next Article:Center for Excellence in Education Announces Inauguration of Research Science Institute at Caltech.
Topics:


Related Articles
Medco Research And Discovery Therapeutics Sign Development And Commercialization Agreement
Adenosine Therapeutics Announces Collaboration and License Agreement with DuPont Pharmaceuticals for New Compounds to Help in Heart Disease Diagnosis.
Adenosine Therapeutics announces heart disease license agreement with Dupont.
Adenosine Therapeutics Announces Venture Financing With the Emerging Technology Partners; Acquires License to Aptus Pharmaceuticals Adenosine...
Adenosine Therapeutics Awarded SBIR Bio-Terrorism Grant.
Adenosine Therapeutics Wins SBIR Grant to Develop Long Lasting A2A Agonists.
Aderis Pharmaceuticals Announces Receipt of $1 Million Milestone Payment for Binodenoson; King Pharmaceuticals begins Phase III testing of...
Bristol-Myers Squibb Medical Imaging and Adenosine Therapeutics Announce Initiation of Phase II Clinical Trials for Novel Pharmacologic Stress Agent.
NIH Awards Adenosine Therapeutics Phase II SBIR Grant to Study Diabetes; Adenosine Therapeutics Compound Has Demonstrated Profound Reduction in...
CV Therapeutics Initiates Phase III Trial of CVT-3146; Triggers $3.0 Million Milestone Payment From Fujisawa Healthcare, Inc.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters